title: Epigenetic therapy leaps ahead with specific targeting of EZH2.
abstract: The Polycomb epigenetic silencing protein EZH2 is affected by gain-of-function somatic mutations in B cell lymphomas. Two recent reports describe the development of highly selective EZH2 inhibitors and reveal mutant EZH2 as playing an essential role in maintaining lymphoma proliferation. EZH2 inhibitors are thus a promising new targeted therapy for lymphoma.
authors.affiliation: Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA. amm2014@med.cornell.edu
authors.forename: Ari
authors.initials: A
authors.lastname: Melnick